within Pharmacolibrary.Drugs.ATC.J;

model J05AG01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.93,
    Cl             = 5.8166666666666667e-05,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0011200000000000001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.013333333333333334,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J05AG01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in the treatment of human immunodeficiency virus (HIV)-1 infection. It is typically used in combination with other antiretroviral agents. Nevirapine is approved for use in adults and children and is available in oral tablet and suspension formulations.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers; oral administration of 200 mg nevirapine twice daily.</p><h4>References</h4><ol><li><p>Podany, AT, et al., &amp; Fletcher, CV (2021). Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention. <i>The Journal of antimicrobial chemotherapy</i> 76(3) 718–721. DOI:<a href=\"https://doi.org/10.1093/jac/dkaa470\">10.1093/jac/dkaa470</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33241266/\">https://pubmed.ncbi.nlm.nih.gov/33241266</a></p></li><li><p>Foster, RH, &amp; Faulds, D (1998). Abacavir. <i>Drugs</i> 55(5) 729–738. DOI:<a href=\"https://doi.org/10.2165/00003495-199855050-00018\">10.2165/00003495-199855050-00018</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9585869/\">https://pubmed.ncbi.nlm.nih.gov/9585869</a></p></li><li><p>Dailly, E, et al., &amp; Raffi, F (2015). Influence of nevirapine administration on the pharmacokinetics of dolutegravir in patients infected with HIV-1. <i>The Journal of antimicrobial chemotherapy</i> 70(12) 3307–3310. DOI:<a href=\"https://doi.org/10.1093/jac/dkv245\">10.1093/jac/dkv245</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26271944/\">https://pubmed.ncbi.nlm.nih.gov/26271944</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J05AG01;
